Citigroup
PCVX icon

Citigroup’s Vaxcyte PCVX Stock Holding History

Citigroup’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,900
Closed -$972K – 6259
2025
Q2 		$972K Buy
+29,900
New +$980K ﹤0.01% 3213
2025
Q1 		– Sell
-12,500
Closed -$1.02M – 5855
2024
Q4 		$1.02M Buy
+12,500
New +$1.24M ﹤0.01% 3350
2023
Q1 		– Sell
-6,200
Closed -$297K – 5767
2022
Q4 		$297K Hold
6,200
– – ﹤0.01% 3513
2022
Q3 		$149K Buy
+6,200
New +$157K ﹤0.01% 3904

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's PCVX Position: Q1 2026 in Review

Citigroup reduced its Vaxcyte (PCVX) stake by 45% in Q1 2026, selling an estimated $5.96M and leaving 132,178 shares worth $7.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

Citigroup first reported a position in PCVX in Q3 2020 and has held it in 23 quarters since. The position peaked at $31M in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Citigroup held 132,178 shares of Vaxcyte worth $7.68M as of Q1 2026.
  • Citigroup sold 109,702 Vaxcyte shares in Q1 2026, an estimated $5.96M.
  • Vaxcyte made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1635 holding.
  • Citigroup first reported a position in Vaxcyte in Q3 2020 and has held it in 23 quarters since.
  • Citigroup's Vaxcyte position peaked at $31M in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.